CG01 has previously been granted patents in the
"The fact that CG01 has been granted patent in two new countries strengthens the project as we are putting together an attractive proposition for a potential partner," says Karin Agerman, Chief Scientific Officer at
About the epilepsy project CG01
CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4,
© Modular Finance, source